Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 18 of 55
A third dose of the AstraZeneca/Oxford Uni vaccine produced higher levels of neutralising antibodies than those found in persons who had recovered naturally from the alpha, beta and delta variants
If approved, Saphnelo would be the first new treatment for systemic lupus erythematosus (SLE) in Europe in more than a decade
Tezspire is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients, the pharma giant said
Citi recommends Buy of AstraZeneca stock on the back of Evusheld announcement.
If the scientists are to be believed, it looks like being double-jabbed offers less protection against the Omicron variant than the Delta one
The blockbuster acquisition by AstraZeneca distorted the figures somewhat, with the number of M&A deals declining in the quarter
The Anglo-Swedish giant is teaming up with Ionis Pharmaceuticals, which is developing a breakthrough drug for a fatal heart condition
It noted that there is no evidence so far that existing vaccines will not provide protection against the Omicron variant
Archive
The UK blue chip index sank even further while US market fall not as bad as feared
The key question is how governments will respond in the event that the ‘nu’ (B.1.1.529) strain spreads.
"In the UK the vaccine was used to vaccinate older people whereas in Europe people thought initially the vaccine doesn’t work in older people"
Six months of protection was maintained despite the surge of the Delta variant
Both Deutsche Bank and UBS have put out (very short) updates post-results
The company is moving away from the not-for-profit pledge made during the pandemic
Builders and building materials
Trading updates are expected from AstraZeneca, while housebuilders Galliford Try and Redrow have annual general meetings.
Barclays sees AstraZeneca as the top pick in the sector.
Swiss group UBS Tuesday restated its 'buy' advice and £100 a share price target
The candidate demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to standard of care
JPM sees Astra achieving core earnings growth of 33%, 27% and 23% in the next three years
The candidate was found to lead to a stronger immune response and to cause fewer side effects compared to its competitor
